Sooma Oy
Sooma Oy is a medical device company that develops non-invasive brain stimulation technology for treating major neurological and psychiatric disorders. The company initial product uses transcranial Direct Current Stimulation (tDCS) to target major depressive disorder, and is CE Marked for clinical use in Europe. The device delivers low-intensity electrical currents through the scalp to modulate neural activity in…
Funding snapshot
About
Sooma Oy is a medical device company that develops non-invasive brain stimulation technology for treating major neurological and psychiatric disorders. The company initial product uses transcranial Direct Current Stimulation (tDCS) to target major depressive disorder, and is CE Marked for clinical use in Europe. The device delivers low-intensity electrical currents through the scalp to modulate neural activity in specific brain regions, offering a drug-free treatment option for patients who have not responded to traditional antidepressant medications. Sooma technology is designed for use in both clinical and home settings, making neuromodulation therapy accessible outside specialized medical facilities. The company is expanding its therapeutic applications beyond depression to address other neurological and psychiatric conditions. Founded in 2013 and headquartered in Helsinki, Finland, Sooma has raised approximately $6.6 million through Series B funding from investors including Voima Ventures, VERGE, EIC Fund, Innovestor, and Lifeline Ventures.
Business model
Wearable Technology > Health and Wellness Devices > Chronic Pain,
Disease Self Management > Neurological Disorders > Therapy > Psychological > Device,
Neurology > Medical Devices > Therapeutic Devices > Psychiatric > Depression
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.